“These findings pave the way for using ALCAR as an adjuvant therapy during long-term use of dexamethasone in MS.”
“… dexamethasone … ALCAR provided marked antioxidant and anti-apoptotic effects represented by significant decrease in MDA, caspase-3 and significant increase in GSH, Bcl-2 expression, and … decrease in CD4+ T cells expression with significant improvement in clinical outcome when compared to untreated EAE group or to dexamethasone treated group.”